Filter By Category
Archives
Share on -
AZILSARTAN MOPIVABIL
Generic Name: AZILSARTAN MOPIVABIL
ABSTRACT -
Azilsartan mopivabil is a lipophilic ester prodrug derivative of azilsartan. It is reported as a potent angiotensin receptor antagonist research compound with potential relevance to hypertension, chronic heart failure, or diabetic nephropathy research. It is not a routine marketed medicine in most jurisdictions. Molecular formula: C₃₈H₃₆N₄O₈; molecular weight: 676.73 g/mol. Development/regulatory status: Investigational/research compound.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved routine dosing schedule is established.
- Any administration must follow an approved research protocol or specialist clinical plan.
- Dose selection depends on formulation, conversion to azilsartan, pharmacokinetics, blood-pressure response, and organ function.
- Do not substitute for approved azilsartan products without medical and regulatory confirmation.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Dizziness, orthostatic symptoms, fatigue, or headache
- Hypotension, especially in volume-depleted patients
- Renal-function changes or electrolyte abnormalities
- Gastrointestinal symptoms such as nausea or diarrhoea
- Rash or hypersensitivity reactions
ALLERGIC REACTIONS -
Hypersensitivity to azilsartan mopivabil or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azilsartan mopivabil should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Renin-angiotensin system blockers, potassium-sparing drugs, potassium supplements, or salt substitutes may increase hyperkalaemia risk.
- NSAIDs may reduce antihypertensive effect and worsen renal function.
- Lithium may require monitoring.
- Other investigational cardiovascular compounds require protocol review.
PREAUTIONS–
- Monitor blood pressure, renal function, potassium, and hydration status if used experimentally.
- Use caution in renal artery stenosis, renal impairment, hepatic impairment, pregnancy, lactation, or heart failure.
- Not for routine unsupervised clinical use.
WARNINGS –
- ARB-class fetal toxicity concerns are expected for azilsartan prodrugs.
- Seek urgent care for syncope, severe dehydration, reduced urination, or allergic reaction.
- Keep out of reach of children.
Share on -
. Developed by